Evidence map›Paper›PMID 42169953›Full record

ArticleJournal of gastrointestinal oncology2026

Jian Hu, Ning Zhang, Yanfen Ma, Nian Zhou, Xiaoqian Wang, Kaige Zhang, Qian Wu, Xiaoqin Wang, Feifei Mao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jian Hu *Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ning Zhang *Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yanfen Ma *Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Nian Zhou *Department of Stomatology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiaoqian WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Kaige ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Qian WuDepartment of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiaoqin WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Feifei MaoDepartment of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths worldwide, with a poor prognosis and high mortality rates. Therapeutic resistance, high recurrence, and limited treatment options contribute to its aggressive nature. The TMF1-regulated nuclear protein 1 (TRNP1) is a highly conserved nuclear protein, recently implicated in tumorigenesis. TRNP1 is upregulated in HCC, but its role in tumorigenesis and immunotherapy resistance remains underexplored. This study investigates the mechanistic roles of TRNP1 in HCC progression through the c-Kit/signal transducers and activators of transcription 3 (STAT3) signaling pathway and its impact on immunotherapy efficacy, particularly in the context of programmed cell death protein 1 (PD-1) blockade. Methods: The expression of TRNP1 was analyzed using bioinformatics tools and confirmed through HCC patient tissue samples. Knockdown and overexpression models of TRNP1 were established in HCC cell lines to investigate its effects on cellular behaviors, including proliferation, migration, invasion, and apoptosis. Transcriptomics explored downstream pathways, identifying the c-Kit/STAT3 signaling axis. Results: TRNP1 was significantly upregulated in HCC tissues compared to adjacent non-cancerous tissues. High TRNP1 expression correlated with reduced overall survival (OS) and disease-free survival (DFS). Conclusions: This study establishes TRNP1 as a tumor-promoting factor in HCC, driving cancer progression via the c-Kit/STAT3 pathway. Moreover,

Indexed as

c-Kit/signal transducers and activators of transcription 3 signaling pathway (c-Kit/STAT3 signaling pathway)hepatocellular carcinoma (HCC)immunotherapyprogrammed cell death protein 1 blockade (PD-1 blockade)TMF1-regulated nuclear protein 1 (TRNP1)

Identifiers

PMID42169953
PMCPMC13187988

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.